Dejan Micic to Randomized Controlled Trials as Topic
This is a "connection" page, showing publications Dejan Micic has written about Randomized Controlled Trials as Topic.
Connection Strength
0.096
-
The risk of respiratory tract infections and interstitial lung disease with interleukin 12/23 and interleukin 23 antagonists in patients with autoimmune diseases: A systematic review and meta-analysis. J Am Acad Dermatol. 2021 Mar; 84(3):676-690.
Score: 0.035
-
Systematic review with meta-analysis: risk of new onset IBD with the use of anti-interleukin-17 agents. Aliment Pharmacol Ther. 2019 08; 50(4):373-385.
Score: 0.033
-
Pharmacologic therapies for severe steroid refractory hospitalized ulcerative colitis: A network meta-analysis. J Gastroenterol Hepatol. 2017 Jun; 32(6):1143-1151.
Score: 0.028